Bejelentkezés Regisztrálj ingyen

Acelrx Pharmaceuticals Inc Kiemelkedően

Mi az Acelrx Pharmaceuticals Inc Kiemelkedően?

A Kiemelkedően az Acelrx Pharmaceuticals Inc - 16.952M

Mi a Kiemelkedően meghatározása?



A fennálló részvények egy olyan vállalat vagy pénzügyi eszköz részvényei, amelyeket a befektetők engedélyeztek, bocsátottak ki és vásároltak meg.

Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.

Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.

Kiemelkedően a Health Care szektor a NASDAQ-on cégekben a Acelrx Pharmaceuticals Inc -hoz képest

Mit csinál Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

kiemelkedően -hoz hasonló cégek Acelrx Pharmaceuticals Inc